




iLUX®

MGD: Know It. Control It.

Choose iLUX® for Personalized
MGD Treatment.

Dry eye is a chronic, progressive, irreversible disease caused by deficiencies in the quantity and quality of meibum or other tear components within the tear film. **Dry eye affects over 30 million people** in the United States,¹ and **86% of dry eye sufferers are reported to have clinical signs of meibomian gland dysfunction (MGD).**² However, **less than half of patients with MGD show symptoms**, and many MGD sufferers may not even know they have it.^{3,4}

Alcon




Layers of the Tear Film

WHAT IS MGD?

Every time you blink, a protective layer of moisture called the tear film coats the front surface of your eye. An essential part of the tear film is an oily layer called meibum. MGD occurs when the meibomian glands that produce meibum get blocked or the secreted meibum is of poor quality—leading to evaporative tear loss. MGD can cause dryness, blurry vision, irritation, and watery eyes, and you may need treatment to alleviate the symptoms. The goal of treatment is to unblock the meibomian glands.

DIAGNOSING MGD

If you regularly use eye drops or have symptoms such as eye dryness and irritation, ask your doctor to evaluate your symptoms. Your doctor will compress your eyelids to assess the level and quality of meibum that is expressed. Healthy meibum is clear and adequate. The more severe the blockage, the thicker and cloudier the meibum appears.





iLUX®: DRY EYE TREATMENT THAT STARTS AT THE SOURCE

The **iLUX® MGD Thermal Pulsation System** delivers treatment directly to the blocked meibomian glands with the goal of clearing the blockages. Therapeutic heat at the optimal temperature is applied to your eyelids. Then, while the oil is thoroughly melted, it is expressed with the precise pressure required. A medical professional will be at your side every step of the way, providing real-time feedback.

Treatment of both eyes takes approximately 8 to 12 minutes.⁵ After the glands are unblocked, it will be easier for the meibum to be released naturally.

Treatment with the **iLUX®** device was shown to significantly reduce dry eye symptoms such as gritty eyes and irritation.⁶ In clinical studies, **iLUX®** was shown to increase meibomian gland function by 300% at 4 weeks post-treatment, compared to baseline.⁶

CONTACT YOUR DOCTOR TODAY

If you experience symptoms such as blurry vision, dry eyes, and irritation, it may be MGD. Even if you aren't experiencing symptoms, the American Optometric Association recommends annual comprehensive eye exams.* This includes an evaluation of the tear film and glands.¹ Learn more about MGD and if treatment with the **iLUX® MGD Thermal Pulsation System** is right for you.

*AOA recommendation based on risk level. Please visit <https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/dry-eye> to learn more about diagnosing and treating dry eye. Talk to your doctor for a personalized recommendation.

Important Information for the iLUX® Device:

The iLUX® Device is used to heat and compress glands in the eyelids of adult patients with a specific type of dry eye, called Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye.

Potential side effects may include eyelid/eye pain requiring stopping the treatment procedure, eyelid/eye irritation or inflammation, temporary reddening of the skin, and other eye symptoms (burning, stinging, tearing, itching, discharge, redness, feeling like there is something in the eye, changes in your vision, sensitivity to light).

Ask your eye care professional for a complete list of safety information for the iLUX® Device.

References:

1. Tear Film and Ocular Surface Society (TFOS). TFOS DEWS II Report. http://www.tearfilm.org/dettreports-tfos_dew_ii_report/32_30/eng/. Published July 2017. Accessed May 9, 2018.
2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea*. 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a.
3. Cochener B, Cassan A, Omiel L. Prevalence of meibomian gland dysfunction at the time of cataract surgery. *J Cataract Refract Surg*. 2018;44(2):144-148. doi:10.1016/j.jcrs.2017.10.050.
4. Viso E, Rodríguez-Ares MT, Abelenda D, Oubiña B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. *Invest Ophthalmol Vis Sci*. 2012;53(6):2601-2606. doi:10.1167/iovs.11-9228.
5. Alcon data on file, 2019.
6. Hardten DR, Schanzlin DJ, Dishler JG, et al. Comparison of a handheld infrared heating and compression device and a thermal pulsation device to treat meibomian gland dysfunction. Paper presented at: 2018 American Society of Cataract and Refractive Surgery–American Society of Ophthalmic Administrators Annual Meeting; April 16, 2018; Washington, DC.